Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCLPeter Martin, John P. Leonard, Sonali M. Smith et al.|Blood|2021Cited by 37
A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed LymphomaPeter Martin, Leandro Cerchietti, Nancy L. Bartlett et al.|Blood|2017Cited by 8